Sunday, October 08, 2017 11:27:42 PM
This seems to be a good potential for a stock to go long - but I have some questions..Hopefully someone can shed some light.
1. From recent news, the company indicated that the recent stock issuance is to allow the Company to fund the "initiation of its Phase 3 clinical program" of RP-G28 for the treatment of lactose intolerance, expected to begin in the first half of 2018. --->The word "initiation" somehow really bothers me as it sounds like, there may be more coming. Can someone shed somelight on this?
2. Potential of >$1.2Billions of prescription market. Can someone translate tha to sales or perhaps potential sp?
3. Timeline of completion of P3 Trial?
Thanks
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM